Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.

Circulation. Cardiovascular quality and outcomes - 1 Sept 2009

Patrick Amanda R, Avorn Jerry, Choudhry Niteesh K

Abstract excerpt

BACKGROUND: CYP2C9 and VKORC1 genotyping has been advocated as a means of improving the accuracy of warfarin dosing. However, the effectiveness of genotyping in improving anticoagulation control and reducing major bleeding has not yet been compellingly demonstrated. Genotyping currently costs $40...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atrial Fibrillation
Share to Cost-Benefit Analysis
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Hemorrhage

Share to Markov Chains

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 20031873
DOI: 10.1161/CIRCOUTCOMES.108.808592

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20031873-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.PMID 20031873Read ↗

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Semantic proximity Read ↗

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Semantic proximity Read ↗

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.Semantic proximity Read ↗

Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.Semantic proximity Read ↗

Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.Semantic proximity Read ↗

Pharmacoeconomic evaluation of warfarin pharmacogenomics.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.Semantic proximity Read ↗

Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of warfarin.Semantic proximity Read ↗

Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.